Ask a question about this product
August 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of August 2016. Featured presentations of August 2016 include the pipeline of CD19-targeted antibody-drug conjugates, the profile of US biotech Igenica Biotherapeutics and the profile of anti-CD25 antibody-drug conjugate ADCT-301 from ADC Therapeutics.
The August 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Merger & acquisitions
Clinical Trial Tracker
Scientific Publication Tracker
Featured ADC Profile: ADCT-301
Featured Company Profile: ADC Therapeutics
Featured Target or Technology Pipeline: CD19 Antibody-Drug Conjugates
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
Contact us at firstname.lastname@example.org to discuss your needs and our ideas of fulfilling them.